1 / 1

CONSORT Diagram for Retrospective and Prospective Inclusion of Patients Treated with AZA

This figure depicts the CONSORT diagram detailing the inclusion process for patients receiving Azacitidine (AZA) in various treatment settings. Initially, 24 patients were treated under compassionate use after FDA approval on May 19, 2004. Following EMA approval on October 24, 2008, 10 additional patients began treatment with AZA. With the commencement of data entry in the eCRF, data cuts for the retrospective patients were finalized by January 20, 2012. In total, 155 patients were included in the dataset for analysis.

tiger-carter
Télécharger la présentation

CONSORT Diagram for Retrospective and Prospective Inclusion of Patients Treated with AZA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1B. CONSORT Diagram B Retrospectively included patients FDA-approval of AZA:19.05.2004 Compassionate use trt. w. AZA in Austria 24 pts. started on AZA EMA-approval of AZA: 24.10.2008 10 pts. started on AZA EC-approval for AAR 01.02.2009 Start of data entry in eCRF 121 pts. started on AZA Prospectively included patients Data cut-off 20.01.2012 Data cleaning 155 pts. included

More Related